Scholars Central

Conference abstractPublished 1 Aug 2022

Personalized expanded Kelleni’s immunomodulatory COVID-19 protocol safely used to manage severe COVID-22: A case-report.

Authors: Mina T. Kelleni

College of Medicine, Minia University, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Early management of COVID-19 is of crucial importance as agreed by experts all over the world. However, there’s no consensus regarding the best protocol that should be adopted. Kelleni’s protocol to manage COVID-19 is based on numerous publications made by the author in reputable international medical journals since April 2020, it’s been safely and effectively used to manage pediatric, adult, geriatric and pregnant COVID-19 patients suffering from mild – severe disease and in this case report, the author suggests that hepatitis/pancreatitis of unknow origin should be thoroughly investigated as a potential novel SARS CoV-2 variant should not be easily excluded and a potential COVID-22 should also be kept in the differential diagnosis in order to avoid repeating the previous mistakes that turned an outbreak into a pandemic that harvested millions of innocent lives. A female in her late seventh decade with a history of chronic hepatitis B viral infection and moderately reduced kidney function suffered a syndrome of severe headache, acute epigastric abdominal pain, nausea, vomiting, confusion, and insomnia that could have been attributed to pancreatitis. However, oxygen saturation, CT chest and laboratory investigations showed evidence of severe COVID-19 while she suffered silent hypoxia and didn’t complain of cough, sore throat, or fever. She was safely and effectively managed using personalized expanded Kelleni’s protocol for three nights only in hospital and she continued treatment at home with over a month follow up until full recovery. We call for routine oxygen saturation screening by pulse oximeter for all high-risk patients currently seeking medical advice for any reason and I suggest if the current criteria to diagnose pediatric hepatitis of unknown origin is modified to include patients with ALT or AST level lower than the currently adopted 500 IU/L, a potential mountain beneath iceberg could be better revealed and examined.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectImmunology & Microbiology
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Mina T. Kelleni”